Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice

Journal of Nanobiotechnology

Research

Senlin Xu¹  Qianmei Wang²  Ruimin Hu³  Wenhao Shen³  Zhansong Zhou³  Jun Zheng³  Yang Yang⁴  Dinglin Zhang⁴ 

[1] Department of Pathology, Southwest Hospital, Army Medical University, Third Military Medical University, 400038, Chongqing, China;Department of Pharmacy, Southwest Hospital, Army Medical University, Third Military Medical University, 400038, Chongqing, China;Department of Urology, Southwest Hospital, Army Medical University, Third Military Medical University, 400038, Chongqing, China;Department of Urology, Southwest Hospital, Army Medical University, Third Military Medical University, 400038, Chongqing, China;Department of Chemistry, College of Basic Medicine, Army Medical University, Third Military Medical University, 400038, Chongqing, China;

关键词: Chronic pelvic pain syndrome;    Dexamethasone;    Nanomedicines;    Targeted therapy;    Smart drug release;   

DOI  :  10.1186/s12951-023-01893-4

 received in 2022-12-29, accepted in 2023-04-11,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundChronic pelvic pain syndrome (CPPS) is a typical symptom of chronic prostatitis (CP) in males that may cause abnormal urination, sexual dysfunction, or depression and significantly affect the quality of life of the patient. Currently, there is no effective treatment for CPPS due to its recurrence and intractability. For synergistic CPPS therapy, we developed pH/reactive oxygen species (ROS) dual-responsive dexamethasone (Dex) nanoformulations using a ROS-responsive moiety and phytochemical modified α-cyclodextrin (α-CD) as the carrier.ResultsDex release from the nanoformulations can be controlled in acidic and/or ROS-rich microenvironments. The fabricated Dex nanoformulations can also be efficiently internalized by lipopolysaccharide (LPS)-stimulated macrophages, prostatic epithelial cells, and stromal cells. Moreover, the levels of proinflammatory factors (e.g., TNF-α, IL-1β, and IL-17 A) in these cells were significantly decreased by Dex nanoformulations treatment through the release of Dex, phytochemical and elimination of ROS. In vivo experiments demonstrated notable accumulation of the Dex nanoformulations in prostate tissue to alleviate the symptoms of CPPS through the downregulation of proinflammatory factors. Interestingly, depression in mice may be relieved due to alleviation of their pelvic pain.ConclusionWe fabricated Dex nanoformulations for the effective management of CPPS and alleviation of depression in mice.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 2

13690_2023_1130_Article_IEq8.gif

40517_2023_252_Article_IEq121.gif

Fig. 4

40517_2023_252_Article_IEq82.gif

Fig. 1

Fig. 1